Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16867168,t1/2,The mean t1/2 of solifenacin was extended from 49.3 to 77.5 hr whereas time to Cmax did not change.,Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16867168/),h,49.3 to 77.5,435,DB01591,Solifenacin
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,0.72,620,DB01591,Solifenacin
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,7.2,621,DB01591,Solifenacin
,28747995,Ki,"Due to the inhibition of the particular intestinal CYP3A4, the obtained Ki values of 14 µM of propiverine (30 mg daily, IR) resulted in a predicted doubling of the AUC for midazolam (CYP3A4 substrate).",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,14,622,DB01591,Solifenacin
,19566112,peak plasma concentrations,"Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10 mg solifenacin dose, respectively.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[ng] / [ml],24.0,106255,DB01591,Solifenacin
,19566112,peak plasma concentrations,"Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10 mg solifenacin dose, respectively.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[ng] / [ml],40.6,106256,DB01591,Solifenacin
,19566112,absolute bioavailability,"Studies in healthy adults have shown that the drug has high absolute bioavailability of about 90%, which does not decrease with concomitant food intake.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),%,90,106257,DB01591,Solifenacin
,19566112,apparent volume of distribution,"Solifenacin has an apparent volume of distribution of 600 L, is 93-96% plasma protein bound, and probably crosses the blood-brain barrier.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),l,600,106258,DB01591,Solifenacin
,19566112,total clearance,"In healthy adults, total clearance of solifenacin amounts to 7-14 L/h.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[l] / [h],7-14,106259,DB01591,Solifenacin
,19566112,terminal elimination half-life,"The terminal elimination half-life ranges from 33 to 85 hours, permitting once-daily administration.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),h,33 to 85,106260,DB01591,Solifenacin
,19566112,renal clearance,"Urinary excretion plays a minor role in the elimination of solifenacin, resulting in renal clearance of 0.67-1.51 L/h.",Clinical pharmacokinetics and pharmacodynamics of solifenacin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566112/),[l] / [h],0.67-1.51,106261,DB01591,Solifenacin
,17251687,elimination half-life,"Total mean +/- S.D. exposure (ng . h/mL) to solifenacin in healthy individuals (1190 +/- 403) was increased in patients with renal disease (mild: 1784 +/- 792, moderate: 1559 +/- 555, severe: 2530 +/- 700), and elimination half-life (mean +/- S.D. [h]) was prolonged (healthy: 68.2 +/- 27.2, mild: 89.1 +/- 34.5, moderate: 90.6 +/- 27.3, severe: 111 +/- 38.3).","Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17251687/),h,68.2,141468,DB01591,Solifenacin
,17251687,elimination half-life,"Total mean +/- S.D. exposure (ng . h/mL) to solifenacin in healthy individuals (1190 +/- 403) was increased in patients with renal disease (mild: 1784 +/- 792, moderate: 1559 +/- 555, severe: 2530 +/- 700), and elimination half-life (mean +/- S.D. [h]) was prolonged (healthy: 68.2 +/- 27.2, mild: 89.1 +/- 34.5, moderate: 90.6 +/- 27.3, severe: 111 +/- 38.3).","Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17251687/),h,89.1,141469,DB01591,Solifenacin
,17251687,elimination half-life,"Total mean +/- S.D. exposure (ng . h/mL) to solifenacin in healthy individuals (1190 +/- 403) was increased in patients with renal disease (mild: 1784 +/- 792, moderate: 1559 +/- 555, severe: 2530 +/- 700), and elimination half-life (mean +/- S.D. [h]) was prolonged (healthy: 68.2 +/- 27.2, mild: 89.1 +/- 34.5, moderate: 90.6 +/- 27.3, severe: 111 +/- 38.3).","Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17251687/),h,90.6,141470,DB01591,Solifenacin
,17251687,elimination half-life,"Total mean +/- S.D. exposure (ng . h/mL) to solifenacin in healthy individuals (1190 +/- 403) was increased in patients with renal disease (mild: 1784 +/- 792, moderate: 1559 +/- 555, severe: 2530 +/- 700), and elimination half-life (mean +/- S.D. [h]) was prolonged (healthy: 68.2 +/- 27.2, mild: 89.1 +/- 34.5, moderate: 90.6 +/- 27.3, severe: 111 +/- 38.3).","Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17251687/),h,111,141471,DB01591,Solifenacin
,15293866,absolute bioavailability,"A single oral dose of solifenacin 10 mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]).",Solifenacin demonstrates high absolute bioavailability in healthy men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15293866/),%,88.0,188506,DB01591,Solifenacin
,15293866,clearance,"A single oral dose of solifenacin 10 mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]).",Solifenacin demonstrates high absolute bioavailability in healthy men. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15293866/),[l] / [h],9.39,188507,DB01591,Solifenacin
,15293866,volume of distribution at steady state,"A single oral dose of solifenacin 10 mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]).",Solifenacin demonstrates high absolute bioavailability in healthy men. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15293866/),l,599,188508,DB01591,Solifenacin
,15293866,absolute oral availability,Pharmacokinetic analyses of single oral and IV doses of solifenacin demonstrated that the drug has a high absolute oral availability of 88%.,Solifenacin demonstrates high absolute bioavailability in healthy men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15293866/),%,88,188509,DB01591,Solifenacin
,15317830,time to maximal concentration,"In the single-dose study, mean time to maximal concentration and elimination half-life ranged from 3.3 to 4.8 and from 40.2 to 57.6 hours, respectively; in the multidose study, the corresponding ranges were 2.9 to 5.8 and 45.0 to 64.8.",Pharmacokinetics and safety of solifenacin succinate in healthy young men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317830/),h,3.3 to 4.8,188899,DB01591,Solifenacin
,15317830,elimination half-life,"In the single-dose study, mean time to maximal concentration and elimination half-life ranged from 3.3 to 4.8 and from 40.2 to 57.6 hours, respectively; in the multidose study, the corresponding ranges were 2.9 to 5.8 and 45.0 to 64.8.",Pharmacokinetics and safety of solifenacin succinate in healthy young men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317830/),h,40.2 to 57.6,188900,DB01591,Solifenacin
,15317830,elimination half-life,"In the single-dose study, mean time to maximal concentration and elimination half-life ranged from 3.3 to 4.8 and from 40.2 to 57.6 hours, respectively; in the multidose study, the corresponding ranges were 2.9 to 5.8 and 45.0 to 64.8.",Pharmacokinetics and safety of solifenacin succinate in healthy young men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15317830/),,2.9 to 5.8,188901,DB01591,Solifenacin
,32055552,AUClast,"The mean (standard deviation) values of AUClast for the test and reference formulations were 486.98 (138.47) and 469.07 (128.29) h·ng/mL, respectively.","Pharmacokinetics comparison of solifenacin tartrate and solifenacin succinate: a randomized, open-label, single-dose, 2-way crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055552/),[h·ng] / [ml],486.98,198677,DB01591,Solifenacin
,32055552,AUClast,"The mean (standard deviation) values of AUClast for the test and reference formulations were 486.98 (138.47) and 469.07 (128.29) h·ng/mL, respectively.","Pharmacokinetics comparison of solifenacin tartrate and solifenacin succinate: a randomized, open-label, single-dose, 2-way crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055552/),[h·ng] / [ml],469.07,198678,DB01591,Solifenacin
,32055552,Cmax,"The mean (standard deviation) values of Cmax for the test and reference formulations were 14.66 (3.85) and 14.10 (3.37) ng/mL, respectively.","Pharmacokinetics comparison of solifenacin tartrate and solifenacin succinate: a randomized, open-label, single-dose, 2-way crossover study in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055552/),[ng] / [ml],14.66,198679,DB01591,Solifenacin
,32055552,Cmax,"The mean (standard deviation) values of Cmax for the test and reference formulations were 14.66 (3.85) and 14.10 (3.37) ng/mL, respectively.","Pharmacokinetics comparison of solifenacin tartrate and solifenacin succinate: a randomized, open-label, single-dose, 2-way crossover study in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055552/),[ng] / [ml],14.10,198680,DB01591,Solifenacin
,15906588,fraction of the drug unbound in plasma,"Solifenacin was highly bound to plasma proteins (fraction of the drug unbound in plasma was approximately 0.02), but there was no clear effect of gender or age.",Effect of age on the pharmacokinetics of solifenacin in men and women. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15906588/),,0.02,212351,DB01591,Solifenacin
